retatrutide sleep apnea Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide Guide: Triple Agonist Research

If youre one of the many people in the world who experiences recurrent UTIs, you may be seeking natural and alternative solutions to avoid excessive exposure to antibiotic drugs

What might a value-based alternative look like

Second, as the main analysis, we used a per-protocol approach to estimate the increased risk of SIS in GLP-1RA vs SGLT-2i users

GLP-1 therapy is still an option when medically appropriate and carefully discussed with your endocrinologist

Finally, although most of the evidence of a potential benefit of GLP-1 RAs in HF originates from CVOTs in type 2 diabetes, it may likely be in the weight management setting that the drug class could be of the highest clinical value, particularly in people with HFpEF

When used responsibly, combining NAD and glutathione may support detoxification, antioxidant protection, and metabolic health